News from milliporesigma A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Aug 19, 2019, 08:00 ET MilliporeSigma Granted 20 CRISPR Patents Total Worldwide

MilliporeSigma, a leader in genome editing, today announced that the European, Israeli, South Korean and U.K. intellectual property offices have issued formal notices allowing MilliporeSigma's patent ...


Jul 18, 2019, 08:00 ET MilliporeSigma and Broad Institute Announce CRISPR License Framework to Encourage Innovation

MilliporeSigma and the Broad Institute of MIT and Harvard today announced an agreement to offer non-exclusive licenses to CRISPR intellectual property (IP) under their respective control for use in...


Jun 20, 2019, 13:30 ET Massachusetts-based Business Sectors of Merck KGaA, Darmstadt, Germany Named 'Best Places to Work' by Boston Business Journal

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that its Massachusetts-based business sectors, MilliporeSigma, EMD Serono and EMD Performance Materials, have ...


May 20, 2019, 08:00 ET MilliporeSigma Joins TRANSVAC2 Program to Advance Vaccine Development and Manufacturing

MilliporeSigma today announced its participation in a collaboration with the Vaccine Formulation Institute and the European Vaccine Initiative. The effort will provide vaccine process development...


Mar 20, 2019, 05:30 ET MilliporeSigma Opens First M Lab™ Collaboration Center in Europe

MilliporeSigma today officially opened its new M Lab™ Collaboration Center in Molsheim, France. The center is MilliporeSigma's first in Europe and ninth worldwide, providing biopharmaceutical...


Mar 19, 2019, 06:30 ET MilliporeSigma to Collaborate with GenScript to Accelerate Cell and Gene Therapy Industrialization in China

MilliporeSigma today announced the signing of a non-binding Memorandum of Understanding with GenScript for a strategic alliance focusing on plasmid and viral vector manufacturing. "Manufacturing of...


Mar 04, 2019, 08:00 ET MilliporeSigma Awarded Canadian CRISPR Nickase Patent for Foundational Genome-Editing Technology

MilliporeSigma, a leader in genome editing, today announced that the Canadian Patent Office has allowed MilliporeSigma's patent application directed to the use of paired CRISPR nickases in eukaryotic ...


Feb 19, 2019, 08:00 ET MilliporeSigma Receives First U.S. Patent for Improved CRISPR Genome-Editing Method

MilliporeSigma, a leader in genome editing, today announced that the United States Patent and Trademark Office has issued a formal notice allowing MilliporeSigma's patent application directed to its...


Dec 10, 2018, 11:30 ET MilliporeSigma and genOway Form CRISPR/Cas9 Strategic Alliance to Develop Rodent Models

MilliporeSigma, a leader in genome editing, today announced a strategic alliance in the CRISPR/Cas9 rodent model market with France-based biotechnology company genOway. "We are committed to making...


Nov 27, 2018, 08:00 ET MilliporeSigma Wins Two R&D 100 Awards for Innovation in 2018

MilliporeSigma today announced that it has won two R&D 100 Awards. The 56th annual R&D 100 Awards program, honoring the 100 most innovative and significant technologies introduced in the past year,...


Nov 05, 2018, 10:00 ET MilliporeSigma Launches BioContinuum™ Platform for Next-Generation Process Improvements

MilliporeSigma today launched its new BioContinuum™ Platform to advance biotherapeutic drug manufacturing through improved efficiency, simplified plant operations and greater quality and consistency. ...


Oct 18, 2018, 06:15 ET MilliporeSigma Announces Agreement to Sell Amnis® Flow Cytometry and Guava® Technologies Businesses to Luminex Corporation

MilliporeSigma today announced the signing of a definitive agreement to sell its Flow Cytometry unit to Luminex Corporation for $75 million.1 The closing of the transaction, expected by the end of...


Oct 04, 2018, 08:00 ET MilliporeSigma Opens M Lab™ Collaboration Center in São Paulo, Brazil

MilliporeSigma today officially opened a state-of-the-art M Lab™ Collaboration Center in Brazil, serving the Latin America region. The center will provide Life Science customers with a shared,...


Aug 15, 2018, 08:00 ET MilliporeSigma Awarded Australian CRISPR Nickase Patent for Foundational Genome-Editing Technology

MilliporeSigma today announced that the Australian Patent Office has allowed the company's patent application for the use of paired CRISPR nickases. Paired nickases represent a significant step in...


Jun 05, 2018, 08:00 ET MilliporeSigma Brings Biotechs Closer to Drug Therapy Production and Commercialization

MilliporeSigma today officially opened North America's first BioReliance® End-to-End Biodevelopment Center providing cell line development services, upstream and downstream process development and...


May 16, 2018, 08:00 ET MilliporeSigma to Use Genome Editing in Study of Gut Bacteria to Benefit Malnourished Children

MilliporeSigma, a leader in genome editing, today announced a collaboration with Washington University in St. Louis that could lead to the optimizing of nutritional supplements to restore a healthy...


Apr 23, 2018, 08:00 ET MilliporeSigma Receives Patent for CRISPR Technology in China

MilliporeSigma, a leader in genome editing, today announced that the Chinese Patent Office has issued a notice granting MilliporeSigma's patent application for the company's CRISPR technology used in ...


Apr 12, 2018, 08:00 ET MilliporeSigma Helps Accelerate Global Access to Affordable Vaccines

MilliporeSigma today announced a partnership with Oxford University's Jenner Institute to develop more robust and scalable vaccine manufacturing processes. This partnership, as well as plans to...


Feb 20, 2018, 06:30 ET MilliporeSigma Receives Two More Patents for CRISPR Technology

MilliporeSigma, a leader in genome editing, today announced that the Korean Intellectual Property Office and the Israel Patent Office have each issued notices granting MilliporeSigma's patent...


Dec 20, 2017, 08:00 ET MilliporeSigma Signs Commercial Supply Agreement with bluebird bio for Viral Vector Manufacturing

MilliporeSigma today announced that it has signed a commercial supply agreement to manufacture viral vectors for bluebird bio, Inc., of Cambridge, Massachusetts, for its use in potentially...


Dec 19, 2017, 08:00 ET Singapore's IP Office to Grant MilliporeSigma's Patent Application for CRISPR Technology

MilliporeSigma, a leader in genome editing, today announced that the Intellectual Property Office of Singapore has issued a "Notice of Eligibility for Grant" for MilliporeSigma's patent application...


Dec 11, 2017, 08:00 ET MilliporeSigma Signs Distribution Agreement with Avanti® Polar Lipids

MilliporeSigma today announced that it has entered into an agreement with Avanti® Polar Lipids to be the exclusive multinational distributor of the Alabama-based company's research lipids portfolio...


Nov 01, 2017, 02:00 ET MilliporeSigma and Samsung BioLogics to Extend Strategic Alliance

MilliporeSigma today announced the signing of a Memorandum of Understanding (MoU) with Samsung BioLogics for a strategic alliance on biopharmaceutical manufacturing and biologics process development. ...


Oct 24, 2017, 08:00 ET Canadian Patent Office to Grant MilliporeSigma's Patent Application for CRISPR Technology

- Patent covers successful integration of an external DNA sequence into the chromosome of eukaryotic cells using CRISPR - First patent allowance for MilliporeSigma's CRISPR technology in North...


Oct 19, 2017, 02:00 ET MilliporeSigma Brings Customers Closer to Gene Therapy Product Commercialization

MilliporeSigma today announced that its Carlsbad, California-based manufacturing facility for the production of BioReliance® viral and gene therapy products has completed both a U.S. Food & Drug...